Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price was down 16.7% on Tuesday . The stock traded as low as C$0.10 and last traded at C$0.10. Approximately 236,500 shares changed hands during mid-day trading, a decline of 15% from the average daily volume of 279,794 shares. The stock had previously closed at C$0.12.
Hemostemix Stock Up 34.5 %
The firm’s 50-day simple moving average is C$0.09 and its 200-day simple moving average is C$0.07. The firm has a market capitalization of C$16.99 million, a PE ratio of -9.75 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- How is Compound Interest Calculated?
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- What to Know About Investing in Penny Stocks
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- How to Invest in Biotech Stocks
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
